Author Archive: Tracy Cooley

Tracy Cooley

Tracy serves as the Director of Events Communications and handles all communications for BIO’s events and emerging company policy issues. She loves blogging and podcasting on all things biotech and believes in the great potential of the industry, looking for every opportunity to spread the message far and wide. Nearly everyone in her family is a golfer, and as such, she has what many people have called a “natural” swing. Sometimes she even hits the ball. Tracy just finished her ninth marathon, and has nearly mastered the skill of one-foot-in-front-of-the-other (usually, sometimes the laces get in the way). The joy of her life is her five-year-old daughter Josephine.

Latest Posts

Inovio CEO Speaks at MIT Conference

Dr. J. Joseph Kim, CEO of Inovio Biomedical Corporation (NYSE Amex: INO), presented keynote remarks on universal DNA vaccines to prevent and treat infectious diseases (such as Influenza) at MIT’s Emerging Technologies Conference. Dr. Kim’s speech focused on the advantages of DNA vaccines versus traditional therapies, which includes speed of development, ease of manufacture, and broader immune responses, as well as the “designer” nature of Inovio’s vaccine approach. The conference took place this week in Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Xoma to develop antibody for H1N1 and H5N1

XOMA Ltd. (Nasdaq:XOMA) is developing an antibody that has been shown by Dana-Farber Cancer Institute and Harvard Medical School researchers to neutralize group 1 influenza A viruses, including H1N1 and H5N1. XOMA will conduct the program under a $2.2 million subcontract with SRI International of Menlo Park, California. The National Institute of Allergy and Infectious Diseases will fund the subcontract. Read the release.

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

The latest from GlobeImmune

Interview with Timothy C. Rodell, M.D., GlobeImmune CEO & President: Can you describe the top priorities or upcoming milestones for your company? Our phase 2 trial in chronic hepatitis C has completed enrollment and we expect to disclose end of treatment data at the annual meeting of the American Association for the Study of Liver Disease in October.  We also expect to present the final data from this trial, sustained virologic response, early in 2010.  Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

Anadys brings together the best of both worlds

Dr. Steve Worland, Ph.D., Anadys Pharmaceuticals, Inc. President, CEO, & Director, discusses the latest developments at the company: Can you describe the top priorities or upcoming milestones for your company? Anadys is focused on the development of ANA598, our non-nucleoside polymerase inhibitor for the treatment of Hepatitis C.  ANA598 is in Phase 2 clinical testing in combination with pegylated interferon-alpha and ribavirin, a current standard of care.  We expect to receive safety and response data Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,

U.S. Patent for Resolvin to Enter Human Trials

Resolvyx Pharmaceuticals, Inc. announced the U.S. Patent and Trademark Office has granted a patent (U.S. Patent 7,582,785) for RX-10045, a Resolvin therapeutic set to enter clinical trials. RX-10045 is a topical eye drop that treats chronic dry eye syndrome. Resolvins are naturally-occurring, small molecule lipid mediators that can be used to treat a wide range of diseases, including asthma, atherosclerosis, rheumatoid arthritis, inflammatory bowel disease, dry eye and retinal disease, among others. Resolvyx has more Read More >

Business of Biotech  |  Leave a comment  |  Email This Post
Tags: ,